The lymphoma is a malignant tumour from the lymph system, usually divided into two categories: HL and non-HhL. The treatment of lymphoma includes chemotherapy, decomposition, immunotherapy, stem cell transplants, etc. In recent years, there has been a significant increase in lymphoma treatment as medical technology progresses, but the full cure depends on a number of factors, including the type of lymphoma, the period, the physical condition of the patient and the therapeutic response.
Can lymphoma be cured?
The concept of “cure” usually means that after the end of treatment, the patient has no relapse or symptoms for a long period of time and there are no visible signs of disease. For some types of lymphoma, especially those who are detected early and treated in a timely manner, the possibility of cure exists. Specifically, the cure of lymphoma is closely linked to the following factors:
(1) Type of lymphoma
The lymphoma is divided into two categories: the lymphoma of Hodgkin and the non-hodgkin lymphoma, which have different levels of cure.
Hodgkin lymphoma: HL is usually an easier type of treatment, especially in early detection when the cure is higher. According to the most recent statistics, the five-year survival rate of lymphoma in Hocking can reach about 80 to 90 per cent, even in some young patients. Hodgkin lymphoma reacts better to chemotherapy and decomposition, so that many patients are able to achieve complete relief during treatment and have greater chances of survival in the long term.
Non-Hotchkin lymphoma: Non-Hotchkin lymphoma (NHL) rates vary according to its variety and pathology. Some of the limitations are higher for non-Hodgkin lymphoma treated early through surgery, chemotherapy or release, and lower for late-stage or recurrent non-Hodgkin lymphoma. For different types of non-Hodgkin lymphoma, such as B cell type and T cell type, treatments and prognosis vary considerably.
(2) Period of lymphoma
The stratification of lymphoma is one of the key factors determining the efficacy and prognosis of treatment. The lymphoma is usually spread from I to IV and, as the condition progresses, the difficulty of treatment and the situation changes.
Early (phases I and II) lymphoma: These patients have relatively high rates of curable treatment, especially of the Hodgkin lymphoma, and many of them have access to long-term survival and cure after early detection and treatment. For non-Hodgkin lymphoma, the rate of early detection and treatment is also ideal.
Late (III, IV) lymphoma: these patients are more difficult to cure. In particular, lymphoma IV usually means that the tumor has spread to multiple organs and tissues, requires more drug intervention and has a higher risk of recurrence. However, with the emergence of new treatments, including immunotherapy and CAR-T-cell therapy, the prospects for late lymphoma treatment have improved.
(3) Age and physical condition of the patient
The age of the patient, the state of health and the response to treatment also affect the likelihood of a cure for lymphoma. Young, healthy patients tend to be more resistant to chemotherapy and treatment, and treatment is more effective. In the case of older persons or people with other basic diseases, treatment may be more risky and more difficult to cure.
Current treatments and prospects for cure
The treatment of lymphoma is also being innovative and the chances of cures are increasing as medical technology advances. The treatment methods currently used include:
(1) Chemotherapy
chemotherapy remains one of the core tools for the treatment of lymphoma, especially in the treatment of non-Hodgkin lymphoma and Hodgkin lymphoma. Chemotherapy inhibits the growth of tumours by killing rapidly divided cancer cells. The length of the chemotherapy process and the type of medication depends on the type and period of lymphoma. For early patients, chemotherapy can achieve better treatment.
(2) Treatment
Treatment is used mainly for local pathologies, especially for the treatment of lymphoma in Hocking. Treatment kills cancer cells through high-energy rays, especially for patients whose tumours are limited to one region. Among the early victims of the lymphoma in Hocking, the decomposition can often help to achieve total relief.
(3) Immunization
Immunization treatment has been one of the important advances in recent years in the treatment of lymphoma, especially the application of monoclon antibodies and immunosuppressants. Immunization treatment identifies and attacks cancer cells through the immune system that mobilizes patients. Immunisation treatments have shown remarkable results for some re-emergence or incurable lymphoma, with some patients achieving long-term relief.
(4) stem cell transplant
Dry cell transplants are an effective treatment for some high-risk patients, especially for relapse or incurable lymphoma. Self-dry cell transplants or amphibious stem cell transplants can help to restore the patient ‘ s blood function and provide new immunization support to help patients resist cancer cells.
(5) CAR-T cell therapy
In recent years, CAR-T-cell therapy has made breakthrough progress in lymphoma treatment. By extracting the patient ‘ s T-cells, and by genetic engineering, making them more responsive to the lethality of lymphoma cells, these cells are transferred back to the patient and the immune system is activated against the tumor. This treatment has had a significant effect on some patients with relapse or incurable lymphoma, some of whom have achieved long-term relief.
Remittance risk and long-term follow-up
Despite significant progress in current treatments, lymphoma remains at some risk of recurrence. In particular, treatment is more difficult for patients with advanced, re-emerging or incurable lymphoma. Repeated lymphoma patients need to undergo regular follow-up and testing in order to detect recurrences at an early stage and to adjust treatment programmes in a timely manner.
Concluding remarks
Overall, the cure for lymphoma depends on a number of factors. The chances of treatment are relatively high for the early detection of Hockin lymphoma, while for some late or recurrent non-Hockin lymphoma, the cure is more difficult. However, the prospects for the treatment of lymphoma have improved significantly as medical technologies continue to improve, especially with the emergence of new treatments such as immunotherapy and Car-T-cell therapy, and many patients have access to long-term relief and even cure. Most importantly, patients need to work closely with doctors to develop individualized treatment programmes to achieve optimal treatment.
